GeneluxGNLX
GNLX
About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Employees: 24
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
170% more call options, than puts
Call options by funds: $27K | Put options by funds: $10K
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
71% more capital invested
Capital invested by funds: $11.5M [Q4 2024] → $19.7M (+$8.2M) [Q1 2025]
30% more funds holding
Funds holding: 57 [Q4 2024] → 74 (+17) [Q1 2025]
5.24% more ownership
Funds ownership: 14.1% [Q4 2024] → 19.34% (+5.24%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
652%
upside
Avg. target
$27
766%
upside
High target
$30
880%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Benchmark Bruce Jackson | 652%upside $23 | Speculative Buy Maintained | 8 May 2025 |
HC Wainwright & Co. Emily Bodnar | 880%upside $30 | Buy Reiterated | 31 Mar 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
1 month ago
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.
Neutral
GlobeNewsWire
2 months ago
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –
Positive
Zacks Investment Research
2 months ago
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
2 months ago
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux.
Neutral
GlobeNewsWire
4 months ago
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
Neutral
GlobeNewsWire
6 months ago
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
Neutral
GlobeNewsWire
7 months ago
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking place November 11-13, 2024, in Boston, Massachusetts.
Neutral
Seeking Alpha
7 months ago
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data from phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected mid-2025. Interim results from phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected 2nd half of 2024.
Neutral
GlobeNewsWire
7 months ago
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer –
Charts implemented using Lightweight Charts™